CTNNB1

1. CTNNB1 Gene Overview

  • Gene Name: CTNNB1 (Catenin Beta 1)
  • Protein Product: β-catenin
  • Chromosome: 3p22.1
  • Normal Function:
    • Component of the Wnt/β-catenin signaling pathway
    • Cell adhesion: links cadherins to the actin cytoskeleton at adherens junctions
    • Gene transcription: In the nucleus, β-catenin acts as a transcription co-activator for Wnt target genes regulating proliferation and differentiation

2. Pathophysiology

Mechanism of β-catenin regulation:

  1. Without Wnt signal → β-catenin is degraded by destruction complex (APC, Axin, GSK3β)
  2. Wnt activation or CTNNB1 mutation → β-catenin accumulates → moves to nucleus → activates oncogenes

3. Tumors Associated with CTNNB1 Mutations

Tumor Type Notes / Frequency
Hepatocellular carcinoma (HCC) ~10–40%, often in β-catenin–activated subtype
Hepatoblastoma (pediatric) Very common, often exon 3 mutations
Desmoid tumors (aggressive fibromatosis) CTNNB1 mutations drive tumor growth
Endometrial carcinoma ~10–20%, usually exon 3 mutations
Medulloblastoma Wnt-activated subgroup (~10%)
Other Rare in colorectal cancer (usually APC loss instead)

4. Clinical and Therapeutic Implications

  • Prognosis:
    • Wnt/β-catenin–activated HCC may have distinct prognosis and therapy response
    • Desmoid tumors often indolent but locally aggressive
  • Targeted therapy:
    • No approved direct β-catenin inhibitors yet
    • Investigational approaches:
      • Wnt pathway inhibitors
      • PORCN inhibitors (block Wnt ligand secretion)
      • Tankyrase inhibitors (promote β-catenin degradation)

5. Pathway Summary

  • Normal: APC + Axin + GSK3β → phosphorylate β-catenin → proteasomal degradation → controlled cell proliferation
  • Mutated CTNNB1: β-catenin escapes degradation → nuclear translocation → transcription of cyclin D1, MYC, and other proliferative genes → tumor growth

Clinical Key Points

  1. CTNNB1 mutations are driver mutations in several cancers, especially hepatoblastoma, desmoid tumors, and a subset of HCC.
  2. Therapies are mostly investigational, targeting the Wnt/β-catenin pathway indirectly.
  3. Mutation testing (often exon 3 sequencing) can guide diagnosis and prognostication in HCC, hepatoblastoma, and desmoid tumors.
Links